Clinical Trial Update: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of B013 in combination with Paclitaxel for platinum-resistant recurrent ovarian cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• B013
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Conditions: Platinum-resistant Recurrent Ovarian Cancer | Phase 2 | Status: RECRUITING